- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Anbio Biotechnology and Oncocyte Compared: Which Stock Reigns Supreme?
A deep dive into the financial performance, product portfolios, and growth prospects of these two manufacturing companies.
Published on Feb. 20, 2026
Got story updates? Submit your updates here. ›
Anbio Biotechnology (NASDAQ:NNNN) and Oncocyte (NASDAQ:IMDX) are both manufacturing companies operating in the healthcare industry. This article compares the two companies across various metrics, including profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership, and risk, to determine which stock is the superior investment.
Why it matters
As investors seek opportunities in the dynamic healthcare sector, understanding the relative strengths and weaknesses of Anbio Biotechnology and Oncocyte can help inform investment decisions. The analysis provides insights into the companies' competitive positioning, growth strategies, and potential for long-term success.
The details
The key findings of the comparison show that Anbio Biotechnology has higher revenue and earnings than Oncocyte, as well as stronger net margins, return on equity, and return on assets. Anbio Biotechnology also has a higher percentage of institutional ownership, indicating strong confidence from large investors. However, Oncocyte has a more diversified product portfolio, with offerings in molecular diagnostics for cancer detection, while Anbio Biotechnology's focus has been primarily on COVID-19 and respiratory disease testing products.
- The analysis covers the fiscal years ended December 31, 2023 and 2022, as well as the six-month periods ended June 30, 2024 and 2023.
- Anbio Biotechnology is currently preparing for the IVDR (In Vitro Diagnostic Regulation) registration of its IVD products, with anticipated approvals by the end of 2027 for high-risk products, 2028 for moderate-risk products, and 2029 for low-risk products.
The players
Anbio Biotechnology
A medical technology company dedicated to the advancement of in vitro diagnostics (IVD) products, with a focus on transforming the diagnostics landscape through personalized and decentralized solutions.
Oncocyte Corporation
A molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer, including the DetermaRx and DetermaIO assays.
What’s next
Anbio Biotechnology is currently preparing for the IVDR (In Vitro Diagnostic Regulation) registration of its IVD products, with anticipated approvals by the end of 2027 for high-risk products, 2028 for moderate-risk products, and 2029 for low-risk products. The successful completion of these regulatory milestones will be crucial for the company's continued growth and expansion in the European market.
The takeaway
This comparison highlights the contrasting strategies and product portfolios of Anbio Biotechnology and Oncocyte. While Anbio Biotechnology has demonstrated stronger financial performance, particularly in the COVID-19 testing market, Oncocyte's focus on cancer diagnostics provides diversification and potential for long-term growth. Investors should carefully consider the companies' respective strengths, market positioning, and growth prospects when evaluating these two healthcare manufacturing stocks.
